Seer, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Omid C. Farokhzad
- Full Time Employees
- 124
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3800 Bridge Parkway Redwood City CA United States of America 94065
- IPO Date
- Dec 4, 2020
- CIK
- 0001726445
- Website
- seer.bio
- Similar Companies
- Business
- Seer, Inc. is a biotechnology company that develops and commercializes innovative proteomics solutions designed to decode the biology of the proteome. Its core product is the Proteograph Product Suite, an integrated solution consisting of proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software that enables unbiased, deep, rapid, and scalable proteomic analysis across complex biological samples. The Proteograph platform provides high-throughput access to proteins and peptides, capturing molecular information including protein variants, and is marketed primarily for research use in academic institutions, life sciences, biopharmaceutical, and biotechnology sectors. Seer operates globally with a presence in the United States, China, Australia, Eastern Europe, Israel, Japan, and South Africa. Founded in 2017 and headquartered in Redwood City, California, Seer has positioned itself as a leader in transformative proteomics technology. Recent major developments include the launch of new product applications for the Proteograph XT workflow specifically tailored for cell lysis proteomics, unlocking deeper intracellular proteomics capabilities. The company has also significantly increased instrument shipments in 2025, nearly tripling shipments in the first nine months compared to all of 2024, reflecting strong market demand. Seer expanded its strategic partnership with Thermo Fisher Scientific to accelerate adoption of the Proteograph Product Suite and continues to foster collaborations with leading service providers to broaden access to unbiased, deep proteomics at scale. Financially, Seer reported approximately $300 million in cash and investments as of late 2024 and projects revenue growth of around 24% for 2025, driven by product innovation, user base expansion, and increasing large-cohort studies in proteomics research. Seer targets proteomics and genomics markets offering research tools for biological discovery and biomarker identification. Its Proteograph platform integrates consumables, instrumentation, and analytical software to support scalable proteomic workflows compatible with widely used laboratory instruments. Seer’s strategic focus on external validation, technological innovation, and collaborative partnerships underscores its commitment to advancing proteomics for scientific research advancement worldwide. This comprehensive approach to proteomics and recent advancements in product applications, strategic partnerships, and market expansion emphasize Seer’s evolving leadership in life sciences and biotechnology sectors. Headquartered in Redwood City, California, Seer operates primarily in the United States with international reach in key global biotech markets. The company went public in 2020 and continues to grow its footprint through technology commercialization and service alliances. The CEO is Omid Farokhzad, who leads the company in driving adoption of its Proteograph technology platform.
Seer Urges Stockholders to Vote “FOR” Seer's Highly Qualified Director Nominees on the BLUE Proxy Card TODAY
Special Committee of Seer's Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.
Radoff-JEC Group Announces ISS' Support of its Case for Change at Seer, Inc.
Seer Board of Directors Issues Letter to Shareholders Setting the Record Straight
The Radoff-JEC Group Issues Letter to Fellow Seer, Inc. Stockholders Correcting the Company's Blatant Rewriting of History
SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with the Schall Law Firm
Seer Board of Directors Issues Letter to Shareholders Demonstrating the Strength and Experience of Seer's Director Nominees
SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with the Schall Law Firm
The Radoff-JEC Group Responds to Chairman and CEO Omid Farokhzad, M.D.'s Proposal to Acquire Seer, Inc.
The Radoff-JEC Group Responds to Chairman and CEO Omid Farokhzad, M.D.'s Proposal to Acquire Seer, Inc.
Seer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation Potential
Seer Announces Receipt of Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.
Seer Prevails in European Patent Opposition as U.S. ITC Opens Investigation into Nanomics
The Radoff-JEC Group Releases Presentation Highlighting Why Seer, Inc. Stockholders Should Vote for Boardroom Change
The Radoff-JEC Group Urges Seer, Inc. Stockholders to Vote for Boardroom Change Today
Seer and Korea University Present Preliminary Data at ASMS 2026 Demonstrating Potential of AI-Driven Plasma Proteomics for Multi-Cancer Screening
The Radoff-JEC Group Highlights Seer Inc.'s and Chairman and CEO Omid Farokhzad, M.D.'s History of Value Destruction
Seer Board of Directors Issues Letter to Shareholders Highlighting the Company's Significant Scientific Progress and Addressing Radoff and Torok's Short-Sighted Campaign
Seer Files Definitive Proxy Materials and Mails Letter to Stockholders
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026